JOIN US FOR A FREE VIRTUAL FORUM:

Treatment Of Schizophrenia:
Focus On Psychopharmacology & Adherence

WEDNESDAY MARCH 15, 2017
12PM EST / 9AM PST LIVE

While treating to remission is the goal in schizophrenia, it remains a target not achieved for many patients. In this virtual forum, Henry A. Nasrallah, MD and Roger Sommi, PharmD, BCPP, FCCP will discuss several considerations in the treatment of patients with schizophrenia. The speakers will explore the consequences of relapse for patients with schizophrenia who discontinue medications, will discuss patient- and system-level indicators that may aid in the identification of those patients at a high potential for discontinuing antipsychotic therapy, and will address how physicians can use basic pharmacogenomics to guide dosing of antipsychotics. The virtual forum will conclude with time for questions from the audience.

Featuring:

Henry A. Nasrallah, MD
Dr. Henry Nasrallah is PsychU's Schizophrenia Section Editor as well as the Sydney W. Souers Professor and Chair of the Department of Psychiatry at Saint Louis University in St. Louis, Missouri. He is also the Editor-in-Chief of Schizophrenia Research and Current Psychiatry.

Roger Sommi, PharmD, BCPP, FCCP
Dr. Roger Sommi is the Associate Dean of the School of Pharmacy, the Vice Chair of the Division of Pharmacy Practice and Administration, and a professor of pharmacy practice and psychiatry at the University of Missouri - Kansas City in Columbia, Missouri.

Walter Lawhorn, PharmD, Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc., will be the moderator of this event. Speakers are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. and will be compensated for participation in this event.

Additional Resources on PsychU:

Basics In Psychopharmacology Presentation
An overview is provided on the basics in psychopharmacology.

- Inflammation & The Two-Hit Hypothesis Of Schizophrenia
- Pharmacokinetics: The Basics
- The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies
- The Evolving Psychopharmacology Of Major Depressive Disorder

REGISTER & ACCESS THESE RESOURCES TODAY AT: www.PsychU.org

PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), Avanir Pharmaceuticals, Inc., and Lundbeck, LLC — committed supporters of the mental health treatment community. No CME credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, Avanir Pharmaceuticals, Inc., and/or Lundbeck, LLC.